Research progress on the antiobesity effects and mechanism of cannabinoid receptor type / 中国药理学通报

ABSTRACT

The CB1 receptor belongs to the G protein-coupled receptor families and are distributed extensively in the nervous system and peripheral tissues. Higher CB1 receptor system activity exhibits in obesity and the CB1 receptor is believed as anorexigenic receptor. It had been showed that rimonabant, a potent and selective antagonist of the CB1 receptor, has the ability to reduce body weight significantly and has been permitted to enter market for obesity therapy recently. Lots of researches have demonstratee that the initial reduction of body weight may be attributed to the severe anorexia induced by rimonabant, the following lasting effect of the drug on body weight loss might be due to an increase induced by it in energy expenditure.